Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

EpiPen Price Hearing: House Plays Bootleg Tape Of Shkreli Event

Executive Summary

Another election year hearing on drug prices yielded more of the same discussions on price hikes and FDA's approval process.

Advertisement

Related Content

Pricing Transparency Policies Not Suited To Generics, GPhA Argues
A Tale Of Two Committees: Which Probed EpiPen Better?
ANDAs Can Get Priority, Eight-Month Reviews Under User Fee Deal
At Drug Pricing Hearing, Innovator Companies Mainly Escape Congressional Wrath

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register